BOOSTER SHOT FOR PHARMA

Local drug cos may chip in to
treat swine flu

Generic Make Of Antiviral Tamiflu Ready

Khomba Singh & Sushmi Dey NEW DELHI

THE swine flu outbreak, classified by the World Health Organisation as a "public health emergency of international concern", may see Indian drug makers pitching in with the generic version of the antiviral Tamiflu as the world looks for quick, affordable options to counter the infection.
    "We have already received proposals from people on behalf of countries in Latin America, Mexico and Israel. We have the capability to supply 1.5 million dosages of the drug within 4-6 weeks," said Amar Lulla, joint MD, Cipla.
    Cipla and other Indian pharma majors can now legally manufacture generic versions of Tamiflu after the patent office in Delhi last month rejected a patent application by Swiss company Roche, which markets the antiviral in India. With this, Indian companies can export the generic versions to countries where Tamiflu is not patented.
    Even in countries where Roche holds the patent, the government concerned can issue compulsory licensing, which essentially means waiving the patent to allow generic players to supply drugs in public interest. Cipla yet to hear from WHO
THE swine flu outbreak has now spread to Canada, parts of Europe, and at least five states in the US, where it has already been declared a public health emergency.
    Swine flu is a form of the virus that normally infects pigs. There are many forms of flu, and the different varieties have the ability to exchange genes with one another. The form of flu that originated in Mexico is a genetic mixture of viruses that have been seen in pigs, birds and people.
    In 2006, when the bird flu outbreak took place, Cipla and Ranbaxy had supplied the antiviral to some Asian countries after the respective governments intervened to buy the generic version.
    "The Indian government already has a stockpile of Tamiflu which it procured during the bird flu outbreak, and one million more will be procured," said to Dr VN Katoch, director general, Indian Council for Medical Research (ICMR).
    Mr Lulla said he is yet to hear from either the WHO or the health ministry, but his company is ready for any eventuality. Cipla sells the drug at Rs 1,000 ($20) for 10 days (a typical course is five days), which is much cheaper than the patented ones.

We have received proposals from people in Latin America, Mexico & Israel. We have the capability to supply 1.5 million dosages of the drug within 4-6 weeks. AMAR LULLA JOINT MD, CIPLA

Free SMS Calls on India Stock Market
DisasterAwareness | Health | Commodities

---

Chat: Y! messenger: wilint Google Talk: ways2invest MSN: akbar_jiwani

Contact Me:

--- @ WiseStamp Signature. Get it now